30 March 2018

Contents

Editorial

• 30 March 2018: vol 19 no 6 – CROI 2018 part 2

Conference reports

• CROI 2018: second reports

• Ibalizumab 24-week phase 3 results and susceptibility to drug-resistant HIV

• Statin use might reduce risk of cancer in HIV positive people

• Rate of bone loss on ART slows after the first year

• Standard dose of dolutegravir sufficient in late pregnancy: interim results from DolPHIN-1 study

• Women’s risk of becoming HIV positive increases three-fold in late pregnancy and four-fold postpartum

• Cure research at CROI 2018: defining and reducing the reservoir and the risks from interrupting treatment

HIV prevention and transmission

• Update on PrEP IMPACT study (March 2018)

Cure-related research

• Elite controllers: sex differences and factors associated with loss of immune control

• Assessing antiretroviral therapy interruptions in HIV cure research

Other news

• US Congress rejects Trump’s proposed cuts to research budget for 2018

On the web

• HCV advocacy training manual

PDFs

• 30 March 2018: vol 19 no 6